Faeth Therapeutics — Third Quarter 2026 Earnings Summary

Faeth Therapeutics reported a net loss of $20.4 million for the third quarter of 2026, driven by increased research and development expenses of $11.7 million and general and administrative costs of $10.4 million. The company's cash, cash equivalents, and marketable securities rose to $174.8 million as of September 30, 2026, compared to $21.2 million at the end of 2025. Regulatory progress included the FDA granting Fast Track designation for PIKTOR combined with paclitaxel in biomarker-selected advanced endometrial cancer. Additionally, preclinical data on PIKTOR was presented at ESMO 2026, and topline results from the Phase 2 PIK-201 trial in endometrial cancer are expected by the end of 2026.